Form 4: Kiromic Biopharma CFO Receives and Modifies Restricted Stock Awards
SEC Form 4 Filing
Brian Hungerford, CFO of Kiromic Biopharma, received restricted stock awards and modified existing restricted stock units.
Summary
- On May 3, 2024, Brian Hungerford, CFO of Kiromic Biopharma, received a restricted stock award of 35,033 shares vesting on April 1, 2025.
- He also received another restricted stock award of 21,900 shares.
- Kiromic BioPharma and Brian Hungerford agreed to cancel 21,900 Restricted Stock Units that were to vest on October 1, 2024, and replace them with 21,900 Restricted Stock Awards vesting on the same date.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock awards to the CFO, neither particularly positive nor negative.
Industry Context
This is a standard SEC Form 4 filing, reflecting changes in beneficial ownership of securities by a company insider. It is common for executives to receive stock-based compensation.
Stakeholder Impact
- The stock awards may incentivize the CFO to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 05/03/2024 | Date of restricted stock award and modification of restricted stock units. |
| 04/01/2025 | Vesting date for 35,033 restricted stock award. |
| 10/01/2024 | Vesting date for 21,900 restricted stock awards. |
| 05/07/2024 | Date of signature on the Form 4 filing. |
Keywords
Kiromic Biopharma, Brian Hungerford, CFO, Restricted Stock Award, Restricted Stock Units, Form 4, KRBP
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.